Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study

BACKGROUND: Vatalanib (PTK787/ZK 222584) inhibits a few tyrosine kinases including KIT, platelet-derived growth factor receptors (PDGFRs) and vascular endothelial growth factor receptors (VEGFRs). We report efficacy and safety results of vatalanib in advanced gastrointestinal stromal tumour (GIST) r...

Descripción completa

Detalles Bibliográficos
Autores principales: Joensuu, H, De Braud, F, Grignagni, G, De Pas, T, Spitalieri, G, Coco, P, Spreafico, C, Boselli, S, Toffalorio, F, Bono, P, Jalava, T, Kappeler, C, Aglietta, M, Laurent, D, Casali, P G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2011
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3111164/
https://www.ncbi.nlm.nih.gov/pubmed/21540861
http://dx.doi.org/10.1038/bjc.2011.151

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3111164/
https://www.ncbi.nlm.nih.gov/pubmed/21540861
http://dx.doi.org/10.1038/bjc.2011.151

Ejemplares similares